Matches in Wikidata for { <http://www.wikidata.org/entity/Q89543800> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q89543800 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q89543800 description "scientific article published on 03 March 2020" @default.
- Q89543800 description "wetenschappelijk artikel" @default.
- Q89543800 description "наукова стаття, опублікована 3 березня 2020" @default.
- Q89543800 name "Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines" @default.
- Q89543800 name "Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines" @default.
- Q89543800 type Item @default.
- Q89543800 label "Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines" @default.
- Q89543800 label "Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines" @default.
- Q89543800 prefLabel "Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines" @default.
- Q89543800 prefLabel "Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines" @default.
- Q89543800 P1433 Q89543800-DA29AE2A-46E3-436F-90EC-21E7D2997784 @default.
- Q89543800 P1476 Q89543800-82C71382-5FEF-4B96-A77D-D7580346DFDA @default.
- Q89543800 P2093 Q89543800-5F1FA191-70D9-4D62-A0BD-63F2423CD18A @default.
- Q89543800 P2093 Q89543800-6C382B30-C2A7-43C1-B8D8-CEBD39E73BFF @default.
- Q89543800 P2093 Q89543800-B9535E8D-2C50-46A8-90FF-08B20B9A7B97 @default.
- Q89543800 P2093 Q89543800-E556160A-DE37-4F97-AECA-3F1814E5B956 @default.
- Q89543800 P31 Q89543800-78C7B3C8-C294-4022-B402-A5F927FDF4C5 @default.
- Q89543800 P356 Q89543800-62035B2D-8CBF-4E2B-AA79-170D5C171B23 @default.
- Q89543800 P50 Q89543800-7567EF2F-EC49-493E-A0CA-5175FB48DB7B @default.
- Q89543800 P50 Q89543800-B17E4F41-0DF1-46D3-A51F-C516817E217B @default.
- Q89543800 P50 Q89543800-C7D66884-550C-49DB-AB79-BE850A84FDEE @default.
- Q89543800 P577 Q89543800-6C93E010-3732-4DB4-A4AB-DCDE5F558867 @default.
- Q89543800 P698 Q89543800-28D6BD75-BF90-422E-8F72-816D4BE32A38 @default.
- Q89543800 P921 Q89543800-8A89F871-0255-4D2F-9E1A-158DEBD4C3DB @default.
- Q89543800 P356 ACS.MOLPHARMACEUT.9B01259 @default.
- Q89543800 P698 32022567 @default.
- Q89543800 P1433 Q3011140 @default.
- Q89543800 P1476 "Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines" @default.
- Q89543800 P2093 "Jean-Philippe Pignol" @default.
- Q89543800 P2093 "Jenny Jooyoung Jeong" @default.
- Q89543800 P2093 "Simmyung Yook" @default.
- Q89543800 P2093 "Yijie Lu" @default.
- Q89543800 P31 Q13442814 @default.
- Q89543800 P356 "10.1021/ACS.MOLPHARMACEUT.9B01259" @default.
- Q89543800 P50 Q50420536 @default.
- Q89543800 P50 Q56607458 @default.
- Q89543800 P50 Q89349001 @default.
- Q89543800 P577 "2020-03-03T00:00:00Z" @default.
- Q89543800 P698 "32022567" @default.
- Q89543800 P921 Q261659 @default.